Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovolic
- Development stage
- Unknown
- Lead developer
- Citi Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ovolic is a fixed-dose combination nutraceutical sachet developed and marketed by Citi Pharma in Pakistan. Each 5g sachet contains myo-inositol (1150 mg), d-chiro-inositol (150 mg), folic acid (200 mcg), and chromium picolinate (100 mcg). It is formulated to support female reproductive health, manage symptoms of polycystic ovary syndrome (PCOS), and improve fertility. The active ingredients work synergistically to regulate menstrual cycles, enhance insulin sensitivity, promote healthy ovulation, and support egg quality.
- Brand names
- Ovolic
02
Targets
DHFR (Dihydrofolate reductase)FOLR1 (FRα)FOLR2 (Folate receptor beta)SLC46A1 (Proton-coupled folate transporter)SLC2A13 (Proton myo-inositol cotransporter (HMIT1))SLC5A3 (Sodium/myo-inositol cotransporter 1 (SMIT1))SLC5A11 (Sodium-coupled myo-inositol transporter 2 (SMIT2))
Beyond the preview
Go deeper on Ovolic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovolic.